Ionis Pharmaceuticals, Inc. announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated ...
Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...
Flamingo Therapeutics ("Flamingo") announced today its participation in the following upcoming investor conferences: ...
Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a ...
Fintel on MSN3d
Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral RecommendationFintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...
Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...
Zacks Investment Research on MSN7d
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to SobiIonis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty ...
Ionis Pharmaceuticals has entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback